Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer
- 254 Downloads
Letrozole is superior to tamoxifen in terms of response and breast preservation rates as primary systemic therapy (PST) in postmenopausal women with ER-positive early breast cancer. However, the optimum duration of endocrine PST remains uncertain.
A phase 2 multicentre, open-label trial was conducted to evaluate the efficacy of letrozole over a preoperative period of 4 months to 1 year. Seventy postmenopausal patients (over 65 years) were recruited in four centers. The primary endpoint was to establish the optimal duration of treatment defined as the time required to attain the maximum response by clinical palpation.
The median age of the group was 79 years (66–91) and the median tumour size 35 mm (range 25–100 mm). No severe adverse events were reported. Fifty-six patients were evaluable for the primary objective. A total of 43 patients (76.8%) achieved an objective response; 29 (51.8%) being partial and 14 (25.0%) complete. The median time to objective response was 3.9 months (95% CI, 3.3–4.5) and the median time to maximum response was 4.2 months (95% CI, 4.0–4.5), although 20 (37.1%) patients achieved the maximal response within 6–12 months.
Letrozole shows a high activity and excellent tolerability as neoadjuvant therapy in elderly patients with endocrine-dependent breast cancer. Four to six months of letrozole as PST is an optimum duration with modest benefits thereafter.
KeywordsLetrozole Neoadjuvant Breast cancer Elderly patients
Unable to display preview. Download preview PDF.
- 1.Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596–2606; erratum in: J Clin Oncol 19:3302PubMedGoogle Scholar
- 2.Mouridsen H, Gershanovich M, Sun Y et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101–2109PubMedCrossRefGoogle Scholar
- 6.Mahillo Ramos E, Llombart Cussac A, Ruiz Simón A et al (2005) Estudio epidemiológico del grupo GEICAM sobre el cáncer de mama en España (1994–1997): Proyecto “El Álamo II” [Epidemiological study of the GEICAM group on breast cancer in Spain (1994–1997): “El Álamo II” Project]. Investigación Clínica y Farmacéutica 2:1697–2554Google Scholar
- 7.Ellis MJ, Buzdar G, Unzeitig GW et al (2010) ACOSOG Z1031: a randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer. J Clin Oncol 28[18s]:abstr LBA513)Google Scholar
- 12.Smith IE, Dowsett M, Ebbs SR et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter double-blind randomized trial. J Clin Oncol 23:5108–5116PubMedCrossRefGoogle Scholar
- 14.Semiglazov V, Kletsel A, Semiglazov V et al (2005) Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). J Clin Oncol 23[(16S):11S]:Abstract 530Google Scholar
- 15.Gil y Gil MJ, Moreno A, Perez X et al (2002) Prognostic factors of tumor response and progression free survival in patients with localized breast cancer treated with toremifene as primary therapy. Proc Am Soc Clin Oncol 21[Suppl]:2979Google Scholar
- 21.Alba E, Calvo L, Albanell J et al; on behalf of GEICAM (2010) Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: a multicenter, randomized phase II study (GEICAM/2006-03). J Clin Oncol 28[Suppl 7]:abstract 500Google Scholar